CRBP News and Press, Corbus Pharmaceuticals Holdings Inc. From 01/29/24

--News Direct-- New York, Jan. 29, 2024 - ( Plato Data ) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December d...

2024-01-26 14:19:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of little-known Corbus Pharmaceuticals (NASDAQ: CRBP ) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key...

2024-01-26 13:34:16 ET More on Corbus Pharmaceuticals Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for Corbus Pharmaceuticals Read the full article on Seeking Alpha ...

2024-01-26 12:32:20 ET Gainers: Corbus Pharmaceuticals Holdings ( CRBP ) +300% . Aclarion ( ACON ) +66% . Panbela Therapeutics ( PBLA ) +36% . Inspire Veterinary Partners ( IVP ) +36% . Rail Vision Ltd ( RVSN ) +34% . Appfoli...

2024-01-26 10:44:09 ET DENVER, Colo., Jan. 26, 2023 ( www.247marketnews.com )- Corbus Pharmaceuticals (NASDAQ: CRBP) reported, this morning, that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner C...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is one of today's top gainers. The company's shares have moved -2.88% on the day to $5.06. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis d...

2024-01-26 08:32:05 ET Losers: Aclarion ( ACON ) 119% . Panbela Therapeutics ( PBLA ) 59% . Processa Pharmaceuticals ( PCSA ) 29% . Corbus Pharmaceuticals Holdings ( CRBP ) 23% . as targeting antibody drug conjugate demonstrates encouragin...

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this dose demonstrated some level of disease control No dose limiting tox...

NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the co...

CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models NORWOOD, Mass., Jan. 09, 2024 (G...